OncoArendi will be present at the following events

ESMO Immuno Oncology Congress Geneva – December 7-10

OncoArendi will present a poster on Friday 8th at 12:30 titled: Novel Dual Arginase ½ Inhibitor OATD-02 Improves Efficacy of Immune Checkpoint Inhibitors (ESMO Immuno Oncology 2017). 

BioEurope Berlin – November 6-8

OncoArendi will present the company during BioEurope in Berlin on the 7th of November at 3PM in room M3, level 3 during the Oncology track. 

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 26 – 30, 2017

Philadelphia, Pennsylvania, USA

OncoArendi will present a poster on the Development of OATD-02, a novel arginase 1 and 2 inhibitor for cancer immunotherapy. (Poster Session B, Sunday Oct 29, 2017 12:30 PM – 4:00 PM, Hall E poster)

ERS – 9-13 September 2017 Milan

OncoArendi will present a poster on The Therapeutic Efficacy of OAT-889 (DualAMCase/CHIT1 Inhibitor) in Comparison to Montelukast in HDM-induced Model of Chronic Airway Inflammation in Mice, on Wednesday 13th, 10th at 8:30 AM. (link to the poster)

ESMO – 8-12 September 2017 Madrid

OncoArendi will present a poster on the development of a novel arginase 1 and 2 inhibitor for cancer immunotherapy, on Sunday, 10th at 1PM. (link: OAT-1746 ESMO 2017)

ATS – Washington 19-24 May 2017

A poster will be presented on Monday, 22nd of May from 9AM (link: poster OAT-889 ATS 2017)

http://conference.thoracic.org

meatnetadmEvents